Search

Your search keyword '"Naclerio, R."' showing total 581 results

Search Constraints

Start Over You searched for: Author "Naclerio, R." Remove constraint Author: "Naclerio, R."
581 results on '"Naclerio, R."'

Search Results

1. Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date

2. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

3. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

4. Rhinitis associated with asthma is distinct from rhinitis alone: The <scp>ARIA‐MeDALL</scp> hypothesis

5. Rhinitis associated with asthma is distinct from rhinitis alone:The ARIA-MeDALL hypothesis

6. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

7. The ARIA-MeDALL hypothesis

8. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

9. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

10. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

11. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

12. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

13. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

14. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

15. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus

16. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

17. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

18. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic - an EAACI/ARIA Position Paper

19. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

20. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy'

21. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

22. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

23. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

24. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries? (Clinical and Translational Allergy, (2020), 10, 1, (16), 10.1186/s13601-020-00323-0)

25. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs

26. Nonallergic Rhinitis-Identifying Gaps in Research: 986

30. Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper

32. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN and AllerGen)

33. Adherence to treatment in allergic rhinitis using mobile technology. the mask study

34. ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

35. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

36. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy': AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project

37. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy': AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project

38. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

39. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)

40. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy'

41. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018) : Change management in allergic rhinitis and asthma multimorbidity using mobile technology

42. Adherence to treatment in allergic rhinitis using mobile technology : The MASK Study

43. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases

44. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma.

48. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)(Clin Transl Allergy (2016) 6 (29) DOI: 10.1186/s13601-016-0116-9)

49. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement

Catalog

Books, media, physical & digital resources